SB
CNTA

Samsara BioCapital’s Centessa Pharmaceuticals CNTA Stock Holding History

Samsara BioCapital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,693,736
Closed -$6.52M – 49
2023
Q1 		$6.52M Hold
1,693,736
– – 1.35% 16
2022
Q4 		$5.25M Hold
1,693,736
– – 1.13% 19
2022
Q3 		$6.81M Hold
1,693,736
– – 1.59% 17
2022
Q2 		$8.25M Sell
1,693,736
-190,360
-10% -$1.22M 2.2% 15
2022
Q1 		$16.9M Buy
1,884,096
+424,403
+29% +$3.87M 4.25% 6
2021
Q4 		$16.4M Sell
1,459,693
-77,840
-5% -$1.05M 3.19% 9
2021
Q3 		$25.7M Hold
1,537,533
– – 4.03% 7
2021
Q2 		$34.1M Buy
+1,537,533
New +$36.1M 4.22% 7

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Samsara BioCapital's CNTA Position: Q2 2023 in Review

Samsara BioCapital sold out of Centessa Pharmaceuticals (CNTA) in Q2 2023, closing a stake of 1,693,736 shares — an estimated $6.52M sold.

Samsara BioCapital first reported a position in CNTA in Q2 2021 and held it in 8 quarters. The position peaked at $34.1M in Q2 2021. 45 funds tracked by Wall St. Rank hold CNTA as of Q2 2023.

  • Samsara BioCapital reported no remaining Centessa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Samsara BioCapital sold 1,693,736 Centessa Pharmaceuticals shares in Q2 2023, an estimated $6.52M.
  • Samsara BioCapital first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Samsara BioCapital's Centessa Pharmaceuticals position peaked at $34.1M in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2023.

Based on Samsara BioCapital's 13F filing for Q2 2023, filed 14 Aug 2023.